A61K 31/704
Attached to a condensed carbocyclic ring system
Official title: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
A61K31/704 (Attached to a condensed carbocyclic ring system) appears on 2,767 US grants and 5,401 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,767
- Published applications
- 5,401
- Assignees
- 2,213
- Inventors
- 10,165
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 2 | 0 |
| 1987 | 5 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 6 | 0 |
| 1991 | 3 | 0 |
| 1992 | 7 | 0 |
| 1993 | 2 | 0 |
| 1994 | 3 | 0 |
| 1995 | 3 | 0 |
| 1996 | 5 | 0 |
| 1997 | 7 | 0 |
| 1998 | 16 | 0 |
| 1999 | 18 | 0 |
| 2000 | 16 | 0 |
| 2001 | 23 | 6 |
| 2002 | 23 | 58 |
| 2003 | 37 | 108 |
| 2004 | 27 | 138 |
| 2005 | 31 | 184 |
| 2006 | 39 | 142 |
| 2007 | 30 | 119 |
| 2008 | 44 | 114 |
| 2009 | 41 | 137 |
| 2010 | 58 | 167 |
| 2011 | 63 | 159 |
| 2012 | 99 | 177 |
| 2013 | 93 | 229 |
| 2014 | 143 | 259 |
| 2015 | 133 | 297 |
| 2016 | 166 | 346 |
| 2017 | 186 | 342 |
| 2018 | 193 | 282 |
| 2019 | 198 | 298 |
| 2020 | 184 | 284 |
| 2021 | 158 | 334 |
| 2022 | 172 | 333 |
| 2023 | 136 | 293 |
| 2024 | 138 | 248 |
| 2025 | 161 | 212 |
| 2026 | 86 | 135 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Therapeutic uses of inhibitors of the RNA-binding protein HuR6 Oct 2026US 12,751,938 B2University of Kansas
- Imidazole-based synthetic lipidoids for in vivo mRNA delivery into immune cells29 Sep 2026US 12,747,214 B2Trustees of Tufts College
- Methods and compositions for treating cancer22 Sep 2026US 12,740,976 B2City of Hope
- Polypeptide that specifically binding to CD123 protein, polypeptide complex, co-delivery system and preparation method and use thereof22 Sep 2026US 12,742,016 B2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
- Piperidine urea derivatives for cancer therapy15 Sep 2026US 12,734,164 B2NeuroPn Therapeutics, Inc.
- Combination therapy glucocorticoids and ginsenoside8 Oct 2026US 2026/0306525 A1Fytagoras
- A combination therapy for cancer treatment8 Oct 2026US 2026/0306633 A1Purdue Research Foundation
- Systems and methods for targeted breast cancer therapies1 Oct 2026US 2026/0294809 A1American University of Sharjah
- Remote control and quantitative monitoring of drug release from nanoparticles based on magnetic particle imaging1 Oct 2026US 2026/0294836 A1Board of Trustees of Michigan State University
- Sirt1 inhibitor or antagonist for use in preventing and/or treating an hpv induced tumour1 Oct 2026US 2026/0294868 A1Universita Degli Studi Del Piemonte Orientale “A. Avogadro”
Most cited
By later US patents
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Therapeutic inhibitor of vascular smooth muscle cells438US 5,981,568 ANeoRx Corporation · 1999
- Liquid delivery compositions268US 5,780,044 AAtrix Laboratories, Inc. · 1998
- Formulations and methods for providing prolonged local anesthesia261US 5,942,241 AEuro-Celtique S. A. · 1999
- Therapeutic inhibitor of vascular smooth muscle cells245US 6,171,609 B2NeoRx Corporation · 2001